Safety and Efficacy of Oral BCX4161 as a Prophylactic Treatment for HAE
Status:
Completed
Trial end date:
2014-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether BCX4161 given as a daily oral prophylactic
treatment is safe and effective in reducing the number of acute attacks in patients with
hereditary angioedema.